Royalty Pharma PLC (NAS:RPRX)
$ 26.6 0.31 (1.18%) Market Cap: 11.82 Bil Enterprise Value: 17.66 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 79/100

Royalty Pharma PLC at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 01:15PM GMT
Release Date Price: $42.44 (+5.41%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Royalty Pharma at the 40th Annual JPMorgan Conference this morning. We think Royalty Pharma is a really unique business that's helping to finance a lot of the innovation we're seeing occurring across the biopharma space. And from the company, we have Pablo Legorreta, the company's founder and CEO, and we have a broader set of the management team come on for the Q&A. So Pablo, a happy New Year and look forward to the presentation and the Q&A. Over to you.

Pablo Gerardo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Thanks, Chris, and I wish you and everyone also a great 2022.

Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Thank you.

Pablo Gerardo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot